Screening cannot begin until site initiation activities are complete.
On October 14, 2026, Estrella Immunopharma announced that Intermountain Health LDS Hospital in Salt Lake City had been activated as the fifth site in its STARLIGHT-1 trial of EB103 for relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company expects screening and enrollment to start after site initiation is finished, according to its announcement of the site activation.
The new site adds trial capacity. It does not provide evidence about EB103’s safety or effectiveness.
STARLIGHT-1 is an open-label Phase I/II study running at multiple centers. In the expansion phase, researchers are evaluating EB103 at the recommended Phase II dose, or RP2D, in adults aged 18 or older with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The study is designed to assess safety and efficacy. Estrella expects the cohort’s data to shape its plans for a future pivotal study.
The trial is registered as NCT06343311 on ClinicalTrials.gov. Other active sites include UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute. Oregon Health & Science University and University Hospitals Cleveland Medical Center are also participating.
EB103 is a CD19-Redirected ARTEMIS® T-cell therapy built on technology licensed from Eureka Therapeutics, Estrella’s parent company. Estrella says ARTEMIS® T cells are designed to activate and regulate through a cellular mechanism closer to an endogenous T-cell receptor than the mechanism used by a traditional CAR-T cell. After infusion, EB103 cells are intended to bind to and destroy CD19-positive cancer cells.
The therapy remains investigational, and activating a trial site does not establish clinical benefit. In a separate cell-therapy development, Stanford Medicine gave its first commercial Orca-T dose after FDA approval in June 2026, as reported in Orca-T rollout coverage.
Estrella CEO Cheng Liu said the hospital’s cellular-therapy experience made it a strong addition to the study. He said activating sites moves the dose-expansion phase forward. The company expects data from the expansion cohort to inform its pivotal-trial strategy for EB103.
